“We” is a small word for a large amount of people. 🩺✨ When we say that we are chasing the miracles of science, we mean that we champion collaboration, partnering with researchers, healthcare professionals, and patient communities to accelerate scientific innovation at Sanofi. Together, we’re chasing the miracles of science so you can chase your dreams. http://spkl.io/6043AZVbX #FutureOfMedicine #ScienceForLife #EmpoweredByScience
About us
We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms
- Website
-
http://www.sanofi.com
External link for Sanofi
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Paris, France
- Type
- Public Company
- Specialties
- vaccines, rare diseases, rare blood disorders, neurology, immunology, oncology, diabetes, cardiovascular diseases, and consumer healthcare
Locations
Employees at Sanofi
Updates
-
Our Q3 2025 Results are now available. Read the press release: http://spkl.io/6045AknEP #SanofiResults
-
Last April, we challenged students worldwide to reimagine large-volume, on-body drug delivery systems. And the response was extraordinary: 📌 400+ participants from 42 countries 🏫 86 submissions from 110+ universities 💡 Ideas brimming with creativity, scientific depth, and impact for patients Top 5 finalist teams – 21 students from 12 universities – now advance to design sprints with expert coaching from IDEO Sanofi mentors. Best of luck to these brilliant minds as they work to transform the future of healthcare! 🧬
-
Results from a phase 2 study evaluating an investigational treatment for Alpha-1 Antitrypsin Deficiency (#AATD), achieved all primary and key secondary endpoints. We are committed to exploring solutions for #RareDisease where unmet need persists. Read our press release: http://spkl.io/6048AX40O
-
-
The FDA has accepted the filing of our supplemental biologics license application for recently diagnosed stage 3 #Type1Diabetes (#T1D) for expedited review through the FDA Commissioner’s National Priority Voucher (CNPV) pilot program. This is another significant milestone as we seek to deliver the first disease-modifying therapy in stage 3 T1D. Read our press release ➡️ http://spkl.io/6047AXivh
-
-
At #ESMO25, we presented phase 2 data that support the potential of our investigational therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). In partnership with Orano Med and Radiomedix, Inc. , we continue to showcase our commitment and ambition of transforming care for people living with rare and difficult-to-treat cancers. Click here for more information ⬇ http://spkl.io/6048AX9tC
-
-
New data from the FLUNITY-HD study published in The Lancet Group assesses the effectiveness of our high-dose #influenza vaccine against hospitalizations in adults 65+ compared to standard-dose influenza vaccines. The study examined Protection Beyond #Flu outcomes in the largest global influenza vaccine effectiveness study of individually randomized older adults, analyzing the impact of the high-dose vaccine on reducing the risk of hospitalizations compared to standard-dose. Read our press release: https://lnkd.in/dCh4pvmZ
-
-
#NEWS: The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of our new treatment for adults with immune thrombocytopenia (#ITP). This recommendation brings us one step closer to helping people in the EU living with this #RareBloodDisorder rooted in immune system dysregulation. We remain committed to advancing scientific innovation to address unmet patient needs in rare and immunological diseases. Read our press release: http://spkl.io/6048AXJHn
-
-
Our brand-new Modulus facilities have been named as one of TIME Magazine 2025 Best Inventions in Medical & Healthcare! 💜 With the ability to produce multiple vaccines and biologics simultaneously, our first-of-its-kind next-generation sites represent the future of pharmaceutical manufacturing, bringing life-changing treatments to patients faster than ever. We’re building the future of healthcare — and this is only the beginning. Learn more: http://spkl.io/6042AVvsY #TIME2025 #Healthcare #Innovation
-
Results from a phase 2 study evaluating a new investigational therapy in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) demonstrated potential benefit in a group of cancers with critical unmet needs. With the results, we remain committed to our ambition of transforming care for people living with rare and difficult-to-treat cancers. Click here for more information⬇️ https://lnkd.in/emUk_FWY CC: Orano Med
-